Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On ...

The 600,000-square-foot campus will produce several types of medicines with room for expansion as digital integration and ...

Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio ...

Chai Discovery collaboration with Bristol Myers Squibb to advance AI-driven antibody discovery: San Francisco, California Saturday, August 22, 2026, 16:00 Hrs [IST] Chai Discovery ...

Bristol-Myers Squibb Company (US1078421011) is drawing investor attention after Zenbexus won accelerated FDA approval on ...

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

Bristol Myers Squibb stock is benefiting from the FDA’s August 13, 2026 accelerated approval of multiple myeloma therapy ...

With markets coming in to a volatile time of year, investors might be more interested in generating income rather than ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Shares of Bristol Myers Squibb ( BMY) were up over 4% in premarket trading to their highest point since early 2023 following a report that the company held merger talks with AstraZeneca ( AZN ), ...

Bristol-Myers Squibb remains a solid, undervalued investment but is no longer a compelling 'Buy' due to muted growth prospects. BMY's growth portfolio now surpasses its legacy portfolio, yet overall ...

For the quarter, Bristol Myers Squibb's overall revenue rose by 3% year over year to $11.5 billion. That was largely due to the growth portfolio, which saw a 12% improvement and contributed $6.2 ...